Potential conflict of interest: Dr. Bruneau received grants from Merck. Dr. Dore consults, advises, is on the speakers' bureau, and received grants from Merck and Janssen. He advises, is on the speakers' bureau, and received grants from Roche. Dr. Grebely advises and received grants from Merck. He owns stock in Gilead.
The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection
Article first published online: 22 NOV 2013
© 2013 by the American Association for the Study of Liver Diseases
Volume 59, Issue 1, pages 109–120, January 2014
How to Cite
Grebely, J., Page, K., Sacks-Davis, R., van der Loeff, M. S., Rice, T. M., Bruneau, J., Morris, M. D., Hajarizadeh, B., Amin, J., Cox, A. L., Kim, A. Y., McGovern, B. H., Schinkel, J., George, J., Shoukry, N. H., Lauer, G. M., Maher, L., Lloyd, A. R., Hellard, M., Dore, G. J., Prins, M. and the InC3 Study Group (2014), The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology, 59: 109–120. doi: 10.1002/hep.26639
The InC3 Study is supported by the National Institute on Drug Abuse (NIDA; award no.: R01DA031056). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIDA or the National Institutes of Health (NIH). The Kirby Institute is funded by the Australian Government Department of Health and Ageing. The views expressed in this article do not necessarily represent the position of the Australian Government. J.Gr. is supported by a National Health and Medical Research Council (NHMRC) Career Development Fellowship. J.B. and N.H.S. are supported by Fonds de la Recherche du Québec-Santé Research Career Awards. B.H. is supported by an Australian Postgraduate Ph.D. Award. G.D. and A.L. are supported by NHMRC Practitioner Research Fellowships. M.H. and L.M. were supported by NHMRC Senior Research Fellowships and M.H. additionally by a VicHealth Senior Research Fellowship. R.S.D. was supported by an NHMRC postgraduate scholarship and a Centre for Research Excellence into Injecting Drug Use postgraduate top-up scholarship. Other research support includes NIH U19 AI088791 (to A.C.), NIH U19 AI066345 (to A.Y.K., G.M.L., and B.H.M.), U19 AI082630 (the National Institute of Allergy and Infectious Diseases; to G.M.L.), R01 DA033541 (NIDA; to A.Y.K.), MOP-103138 and MOP-210232 (the Canadian Institutes of Health Research; to J.B. and N.H.S.), and the Netherlands National Institute for Public Health and the Environment (to M.Svd.L. and M.P.). J.Ge. is supported by the Sydney Medical Foundation and grants from the NHMRC.
- Issue published online: 20 DEC 2013
- Article first published online: 22 NOV 2013
- Accepted manuscript online: 2 AUG 2013 05:29AM EST
- Manuscript Accepted: 16 JUL 2013
- Manuscript Received: 19 APR 2013
- 14InC Study Group. Cohort Profile: The International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC3) Study. Int J Epidemiol 2012 Nov 30. doi: 10.1093/ije/dys167., , , , , , et al.; on behalf of the
- 32Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis 2012;12:408–414., , , , , , et al.